Prostate cancer (PCa) represents the second most common solid cancer in men worldwide. In the last decades, the prostate health index (PHI) emerged as a reliable biomarker for detecting PCa and differentiating between non-aggressive and aggressive forms. However, before introducing it in clinical practice, more evidence is required. Thus, we performed a systematic review and meta-analysis for assessing the diagnostic performance of PHI for PCa and for detecting clinically significant PCa (csPCa).
Agnello, L., Vidali, M., Giglio, R.V., Gambino, C.M., Ciaccio, A.M., Lo Sasso, B., et al. (2022). Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 60(8), 1261-1277 [10.1515/cclm-2022-0354].
Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis
Agnello, Luisa;Giglio, Rosaria Vincenza;Gambino, Caterina Maria;Ciaccio, Anna Maria;Lo Sasso, Bruna;Ciaccio, Marcello
2022-05-16
Abstract
Prostate cancer (PCa) represents the second most common solid cancer in men worldwide. In the last decades, the prostate health index (PHI) emerged as a reliable biomarker for detecting PCa and differentiating between non-aggressive and aggressive forms. However, before introducing it in clinical practice, more evidence is required. Thus, we performed a systematic review and meta-analysis for assessing the diagnostic performance of PHI for PCa and for detecting clinically significant PCa (csPCa).
| File | Dimensione | Formato | |
|---|---|---|---|
|
Prostate health index (PHI) as a reliable biomarker for prostate cancer.pdf
accesso aperto
Descrizione: Articolo
Tipologia:
Versione Editoriale
Dimensione
1.92 MB
Formato
Adobe PDF
|
1.92 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
